Correction: The structural framework, cellular composition, molecular factors, and disease-related expressions of the gut-liver-immune interaction

Overview

This correction addresses the inclusion of author Jung A Eom as an equal contributor to the original article on the gut-liver-immune axis.

Background

Understanding the gut-liver-immune axis is crucial as it plays a role in various diseases, including liver conditions and autoimmune disorders.

Data Highlights

No numerical or trial data provided in the correction article.

Key Findings

• Jung A Eom was mistakenly excluded as an equal contributor in the original publication.
• The gut-liver-immune axis is organized around barriers that regulate microbial and dietary signals.
• Disruption of this axis can lead to inflammation in liver diseases.
• Current guidelines emphasize risk assessment in metabolic dysfunction-associated liver disease.
• Understanding this axis can inform treatment strategies for liver transplantation and fatty liver disorders.

Clinical Implications

Clinicians should consider the role of gut health in liver disease management.

Conclusion

This correction highlights the inclusion of Jung A Eom as an equal contributor.

Related Resources & Content

1. Yoon SJ, Eom JA, Suk KT, Frontiers in Immunology, 2026 -- Correction: The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations
2. Infection — Investigating Gut Barrier Dysfunction's Impact on Postoperative Outcomes Following Liver Transplantation: Insights into Pathophysiology and Treatment Options
3. Journal of Gastrointestinal Surgery — The Impact of Intestinal-Derived Lipopolysaccharides and Gut Barrier Function on Fatty Liver Disorders
4. Frontiers in Immunology — Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets
5. Journal of Gastroenterology — The Interplay of Diet, Microbiota, and Genetic Factors in Inflammatory Bowel Disease Development
6. Investigating Gut Barrier Dysfunction's Impact on Postoperative Outcomes Following Liver Transplantation
7. The Impact of Intestinal-Derived Lipopolysaccharides and Gut Barrier Function on Fatty Liver Disorders
8. Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets
9. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10. The gut–liver axis in chronic liver diseases: An integrative immunopathological perspective bridging animal models and human evidence - ScienceDirect
11. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine